ProQR Therapeutics N.V. (NASDAQ: PRQR) announced preliminary safety and pharmacokinetic data from its Phase 1 trial of AX-0810, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE